RxDoctor Payments Data

Clay Holley, MD

Ophthalmology · Butte, MTNPI 1346565330

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 83.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $265 and has fallen 67.4% since, to $86 in 2025.

$784in general payments, 2019–2025

Across 30 payments — averaging $26.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$653
  • AbbVie$117
  • Sight Sciences, Inc.$14
$12,500in research payments, 2019–2025

Across 2 payments — averaging $6250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$13K

What the payments were for

  • Travel & lodging$122%
  • Food & beverage$77298%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon26$653
AbbVie(2 entities)3$117
Sight Sciences, Inc.1$14

How this compares

$784 in reported general payments places this provider in the 65th percentile of 52 ophthalmology providers in Montana.

See all ophthalmology providers in Montana

Medicare billing

Part B allowed, 2024
$2,955,463
Medicare patients
1,713
Services billed
16,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine38$35,661
LumiganBimatoprost49$23,551
Difluprednate119$12,417
Prednisolone Acetate202$10,467
MoxifloxacinMoxifloxacin Hcl355$6,580
CombiganBrimonidine Tartrate/Timolol11$5,210
Latanoprost355$4,249
RhopressaNetarsudil Mesylate13$3,967
Brimonidine Tartrate89$3,950
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$3,501
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat125$1,932
Travoprost19$1,835
Ketorolac Tromethamine134$1,747
Timolol Maleate89$1,431
Acyclovir34$585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$117$64,42398 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 52 ophthalmology providers in Montana.

Other ophthalmology in Butte

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →